Company Information

 

Pro Medicus Limited (ASX: PME)

Pro Medicus Limited is an Australia-based healthcare informatics company. The Company provides a full range of medical imaging software and services to hospitals, imaging centers and health care groups in Australia, North America and Europe. Its products include Visage RIS, Visage RIS/PACS, Visage 7, Visage Ease Pro and Visage Ease.

Its Visage RIS is a radiology information systems (RIS) medical software for practicing of management, training, installation and professional services. Visage RIS capabilities include patient registration, billing, scheduling, typing, HL7 integration, financial reporting, digital dictation and voice recognition integration.

Its Visage 7.0 is a healthcare imaging software that provides clinicians with visualization capability for rapidly viewing 2-D, 3-D and 4-D medical images and picture archive and communication system (PACS)/digital imaging software that is sold directly and to original equipment manufacturers (OEM), training, installation and others.

 

Top Australian Brokers

 

REVENUE IN AUD (TTM)

166.33m

NET INCOME IN AUD

82.79m

Year on year Pro Medicus Ltd grew revenues 30.63% from 127.33m to 166.33m while net income improved 36.52% from 60.65m to 82.79m.

 

Pro Medicus Limited (ASX: PME) Live Chart

 

Pro Medicus Limited (ASX: PME) Forecast

Based on 4 Wall Street analysts offering 12 month price targets for Pro Medicus Limited The average price target is AU$124.63 with a high forecast of AU$136.00 and a low forecast of AU$115.00. The average price target represents a -9.50% change from the last price of AU$137.71.

 

Latest ASX News

 

Pro Medicus Limited (ASX: PME) Performance

 

Pro Medicus Limited (ASX: PME) Fundamentals

 

Pro Medicus Limited (ASX: PME) Competitors

 

Don’t Buy Just Yet

You will want to see this before you make any decisions.

Before you decide which shares to add to your portfolio you might want to take a look at this special report we recently published.

Our experts picked out The 5 best ASX shares to buy in 2024.

We’re giving away this valuable research for FREE.

Click below to secure your copy